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A B S T R A C T
The alternative respiratory chain (aRC), comprising the alternative NADH dehydrogenases (NDX) and quinone
oxidases (AOX), is found in microbes, fungi and plants, where it buﬀers stresses arising from restrictions on
electron ﬂow in the oxidative phosphorylation system. The aRC enzymes are also found in species belonging to
most metazoan phyla, including some chordates and arthropods species, although not in vertebrates or in
Drosophila. We postulated that the aRC enzymes might be deployed to alleviate pathological stresses arising from
mitochondrial dysfunction in a wide variety of disease states. However, before such therapies can be con-
templated, it is essential to understand the eﬀects of aRC enzymes on cell metabolism and organismal phy-
siology. Here we report and discuss new ﬁndings that shed light on the functions of the aRC enzymes in animals,
and the unexpected beneﬁts and detriments that they confer on model organisms. In Ciona intestinalis, the aRC is
induced by hypoxia and by sulﬁde, but is unresponsive to other environmental stressors. When expressed in
Drosophila, AOX results in impaired survival under restricted nutrition, in addition to the previously reported
male reproductive anomalies. In contrast, it confers cold resistance to developing and adult ﬂies, and counteracts
cell signaling defects that underlie developmental dysmorphologies. The aRC enzymes may also inﬂuence life-
span and stress resistance more generally, by eliciting or interfering with hormetic mechanisms. In sum, their
judicious use may lead to major beneﬁts in medicine, but this will require a thorough characterization of their
properties and physiological eﬀects.
1. Introduction
Protists, fungi and plants possess an auxiliary respiratory system in
their mitochondria, which buﬀers metabolic stresses that arise from
limitations on electron ﬂow in the system of oxidative phosphorylation
(OXPHOS). This alternative respiratory chain (aRC) comprises re-
presentatives of just two classes of enzyme: one or more alternative
NADH dehydrogenases (NDX), that transfer electrons from NADH to an
intermediate electron carrier, ubiquinone [1], and alternative oxidases
(AOX), that complete electron transfer from ubiquinol directly to
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oxygen [2]. In terms of their net redox chemistry, NDX and AOX can
functionally replace respiratory complex I (cI, NADH:ubiquinone oxi-
doreductase) and complexes III (cIII, ubiquinol:cytochrome c oxidor-
eductase) plus IV (cIV, cytochrome c oxidase) of the OXPHOS system,
respectively.
In contrast to the standard OXPHOS complexes of the mitochondrial
respiratory chain (RC), the alternative enzymes have ﬁve distinct
properties. First, they are each composed of a single polypeptide.
Second, their reaction chemistry is non proton-motive, instead dis-
sipating the released free energy as heat. Third, they are universally
coded only by the nuclear genome. Fourth, they are refractory to the
commonly used OXPHOS inhibitors. Finally, their biochemical prop-
erties limit their activity to metabolic conditions where they are func-
tionally required, at least in the case of AOX. As a result, AOX may be
considered a self-regulating enzyme that does not ‘short-circuit’ the
OXPHOS system, except when the latter is already dysfunctional. In
plants, the basis of this restriction is relatively well understood, in that
the enzyme only becomes active when the substrate pool of reduced
quinones accumulates to elevated levels, that would be considered
abnormally high in non-photosynthetic organisms [3,4]. In eﬀect, the
enzyme displays a much higher Km for ubiquinol than does cIII. This
property has been assumed to apply to AOX from other taxa, but has not
yet been formally demonstrated.
In various species, AOX has been reported to become activated by
metabolites such as pyruvate [3,5–7] and other organic acids [8,9], that
may accumulate under conditions of RC overload or inhibition, or in
response to speciﬁc metabolic stresses. In some taxa the aRC enzymes
have also been shown to be regulated by heat stress [10], calcium
[10,11] and purine nucleotides [7,9,12]. The molecular basis of these
phenomena, or even whether regulation is direct or indirect, is mostly
not known, although activation of AOX in plants is relatively well un-
derstood. In this case, AOX is believed to exist normally as a dimer,
which is activated (most likely by thioredoxin) when the inter-subunit
disulﬁde bridge is broken. Further activation is brought about by the
allosteric binding of pyruvate and/or other organic acids [13]. Plant
AOX is also regulated at the level of gene expression in many contexts
where its presence confers predictable resistance against various me-
tabolic stresses, including drought, heat, cold, salt and even pathogen
invasion [14,15].
Much less is known about the metabolic regulation of NDX, which is
found in diﬀerent sub-mitochondrial compartments, and is likely to
operate subject to the availability of substrate in these locations. In the
yeast Saccharomyces cerevisiae, which lacks cI, the NDX variants Nde1
and Ndi1, which respectively catalyze NADH oxidation at the exterior-
and interior-facing sides of the inner mitochondrial membrane, may be
co-regulated with the rest of the OXPHOS machinery.
In plants, the aRC enzymes are also believed to maintain mi-
tochondrial metabolic processes and redox homeostasis during day-
light, at least under stress conditions [16], when excess ATP production
by photosynthesis may restrict ﬂux through the mitochondrial RC. Two
other physiological traits conferred by aRCs are thermogenesis and
regulation of aging. aRC enzymes do not conserve the free energy of
biological oxidations by charge separation across the inner mitochon-
drial membrane. Instead, they dissipate the energy as heat. But this heat
can also be harnessed. The most spectacular examples of aRC-based
thermogenesis are in plants, where the released heat is used to volatilize
insect attractants, as in the ﬂowers of arum lilies [17,18]. In fungi, a
well documented example of a life-cycle shift from OXPHOS to alter-
native respiration underlies the switch from vegetative growth to long-
term maintenance in Podospora anserina. In senescent cultures the aRC
acts to replenish primary electron carriers such as NAD in their oxidized
form but does not support continuous growth. However, it also gen-
erates far less reactive oxygen species (ROS) than the OXPHOS system,
thus limiting oxidative damage and facilitating long-term survival [19].
Defence against excess ROS may be a common function at least of AOX,
since the accumulation of reduced quinols that triggers its activation
potentially favours the passage of single electrons to oxygen both at cIII
and, via reverse electron ﬂow, at cI. Conversely, since ROS has also
been posited to serve a signaling function, especially in regard to re-
verse electron transport at cI [20], AOX activation might interfere with
or modify cell signaling pathways in some contexts, with important
physiological consequences.
The aRC enzymes are also found in bacteria, and in representative
organisms from many metazoan phyla [21], including some arthropods
and some chordates [22,23]. Intriguingly, they appear to have been lost
during the course of evolution in what are commonly regarded as the
crown groups of metazoan evolution: the vertebrates and the more
advanced insects, such as honeybees or ﬂies [21,22] as well as, most
likely, the cephalopod molluscs. Whilst at least some physiological
functions of aRC enzymes in lower eukaryotes and plants are relatively
well established, the roles they play in animals are almost completely
unknown. They have been proposed to facilitate adaptation to en-
vironmental stresses and transitions [22], but experimental data sup-
porting this concept remains to be gathered. In plants, some alternative
NADH dehydrogenases can use NADPH as a substrate, but this issue is
one of many that have not been explored in regard to the enzyme in
animals.
We reasoned that, since many of the same stresses against which
AOX provides a defence in plants and lower eukaryotes also occur pa-
thologically in humans, as a result of mitochondrial OXPHOS dys-
function, deploying aRC enzymes xenotopically might help alleviate the
associated disease states [24]. To test and develop this concept, we set
out to examine the properties conferred upon cells and model organ-
isms by expression of metazoan aRC enzymes.
In pioneering experiments, Yagi and colleagues had already de-
monstrated that yeast Ndi1 could be expressed in human cells, and
could functionally replace the redox activity of cI [25–29]. By devel-
oping this concept further, they showed its potential in pathological
models of cI-related diseases in rodents [30–32], informing and in-
spiring our work using the metazoan enzymes. For our own experi-
ments, we selected, as a source, the group of animals closest to humans,
but which still retains genes for both AOX and for NDX; namely the
tunicates, a sister-group to the vertebrates.
In initial trials we were able to express in human cells the AOX from
the tunicate Ciona intestinalis [33]. The Ciona AOX protein was routed to
mitochondria via its own, intrinsic N-terminal mitochondrial targeting
peptide. It conferred resistance to OXPHOS toxins such as antimycin A
or cyanide in isolated mitochondria or in whole cells. More remarkably,
when introduced transgenically into Drosophila or into the mouse, AOX
could be expressed ubiquitously, with almost no detectable eﬀect on
phenotype [34]. Transgenic expression in Drosophila of the Ciona NDX
[35], or the single-subunit NADH dehydrogenase Ndi1 from yeast [36],
was also achieved with hardly any detectable eﬀect on normal devel-
opment or physiology, at least under non-stressed conditions.
Given these ﬁndings, we and others have proceeded to test how far
these transgenes provide protection against physiological stresses that
arise through, or are mediated, by mitochondrial dysfunction, com-
mencing with studies in Drosophila. Although AOX was unable to rescue
a null mutation in a subunit of cIV [34], it was able to compensate, at
least partially, for the eﬀects of cIV knockdown directed at speciﬁc
subunits and tissues [37,38], as well as for the eﬀects of a heteroplasmic
mtDNA mutation aﬀecting cytochrome oxidase [6]. More intriguingly,
AOX expression was able to attenuate the pathological phenotypes of
several diﬀerent neurological disease models, including two Drosophila
models of Parkinson's disease [34,39] and one of Alzheimer's disease
[40]. The exact mechanisms behind these phenotypic transformations
remain to be elucidated, but alleviation of excess ROS production due
to blocked electron ﬂow has been put forward as one plausible,
common explanation. Conversely, AOX was unable to improve the
phenotype of a ﬂy model of mitochondrial translational disease (tko25t),
which exhibits developmental delay and mechanically induced sei-
zures, associated with a decreased activity of all four OXPHOS
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complexes that are dependent on mitochondrial translation products
[41]. Co-expression of Ndi1 actually worsened the phenotype, sug-
gesting that the underlying defect is insuﬃcient ATP production rather
than disturbed redox or metabolic homeostasis. AOX was also unable to
rescue lethal mutations in the mtDNA helicase (Twinkle) or DNA
polymerase γ, as well as the lethality produced by global knockdown of
these genes [42].
Flies expressing Ndi1 showed evidence of increased lifespan, which
was originally suggested to be due to a compensation of oxidative stress
[36]. However, this eﬀect appears to result from a paradoxical hormetic
process, in which the constitutive expression of Ndi1 actually increases
mitochondrial ROS production due to reverse electron ﬂow through cI,
which then activates stress responses that prevent oxidative damage
throughout life [43].
Whilst our ﬁndings in Drosophila are in some ways remarkable,
implementing aRC enzymes as actual therapy remains only a distant
goal. The range of medical conditions in which mitochondrial RC or
OXPHOS dysfunction is a contributory or essential factor is very broad,
spanning from primary mitochondriopathies caused by mutations in
mtDNA or in the apparatus of mtDNA maintenance and expression
[44,45], through to common disease entities where mitochondrial dis-
ruption is due to ischemia/reperfusion injury, oxidative or proteotoxic
stress, toxic damage or other external causes. We need to elucidate in
much greater detail which of these conditions is alleviated by the ex-
pression of aRC enzymes, using the most appropriate animal models.
Thus, a major thrust of current work is to test, using mouse models now
available, how far AOX (or NDX/Ndi1) can negate the pathological
consequences of mitochondrial dysfunction in all of these contexts. The
focus of these studies will increasingly be on cardiovascular and neu-
rological diseases, where the importance of mitochondrial dysfunction
is now widely recognized.
Despite the encouraging ﬁndings to date in animal models, the
potential problems in the use of aRC enzymes in therapy need to be
considered in much greater detail. We need to be sure that their acute
or chronic administration does not have harmful long-term con-
sequences; in particular when the body is stressed in ways that may or
may not be related to the original or underlying condition that
prompted their use. Not all types of mitochondrial dysfunction are
equivalent, and not all tissues respond in the same manner to a given
biochemical defect or external stress.
In order to address the many issues arising from the potential use of
metazoan aRC enzymes in future therapy, it is necessary to establish in
ﬁner detail their inherent properties, in particular when and how they
become enzymatically active and how they aﬀect model organisms
under stress conditions where they may become activated. The wide
range of medical conditions associated with mitochondrial dysfunction,
and against which aRC enzyme-based therapies might be eﬀective,
combined with the diversity and complexity of their regulation already
known from the plant and microbial world, mean that this task is vast
and complicated.
As a ﬁrst step towards this goal, we here set out to investigate as-
pects of the biology of aRC enzymes in the animal source that we in-
itially selected, C. intestinalis. In particular, in order to obtain clues on
their probable physiological functions, we tested how their expression
is modiﬁed by external conditions, focusing on stressors found in their
natural environment. In a parallel set of studies, we investigated how
the expression of aRC enzymes, speciﬁcally AOX, can modify the phy-
siological responses of model organisms under stressful environmental
conditions, focusing initially on temperature and nutrition, and on the
already well characterized Drosophilamodels which are also much more
easily manipulated than their mammalian counterparts.
2. Materials and methods
2.1. Ciona specimens, maintenance and stress treatments
Ciona adults were supplied as living specimens by the Station
Biologique de Roscoﬀ. Prior to the experiments, they were acclimated
to laboratory conditions for 24–48 h without feeding, at 18 °C in glass
aquaria at a density of one animal per 2.5 l artiﬁcial sea water (Reef
Crystals Aquarium Systems, Sarrebourg, France). To test the eﬀects of
sulﬁde, sodium sulﬁde nonahydrate (Sigma Aldrich) was added so as to
reach combined concentrations of dissolved free sulﬁdes of 100 and
300 μM. To test the eﬀects of altered oxygen levels, normoxia was de-
ﬁned as the equilibrium state with atmospheric oxygen. Hypoxic con-
ditions were established by displacement of air by nitrogen gas, and
hyperoxic conditions by oversaturation using gaseous oxygen. Oxygen
levels were monitored using an optical ﬁbre probe and associated
software (OxyView - PST3-V6.02, Precision Sensing GmbH, Germany)
and adjustments were made so to maintain stable conditions
throughout each experiment. For details of other stresses applied, see
Supplementary Data File.
2.2. RNA extraction and analysis
Total RNA was extracted from frozen dissected Ciona organs (ovary,
heart and stomach) by homogenization in 1ml TRI Reagent (Molecular
Research Center, USA) using ceramic beads, for 3× 20 s at 4000 rpm
(PowerLyzer 24 Bench Top Bead-Based Homogenizer; MO BIO
Laboratories, USA). After chloroform extraction, followed by cen-
trifugation at 12,000gmax for 15min at 4 °C, RNA was precipitated from
the aqueous phase by isopropanol at −20 °C for 1 h, followed by cen-
trifugation at 12,000gmax for 8min at 4 °C. Pellets were washed in 75%
ethanol, air dried, and resuspended in RNase-free water at 60 °C for
10min. RNA was prepared from frozen neural complex samples using
Single Cell RNA Puriﬁcation Kit (Norgen Biotek, Canada). Samples were
manually homogenized in 100 μl lysis buﬀer using plastic pestles, fol-
lowed by incubation at 42 °C for 5min, subsequent vortexing for 15 s,
and thereafter treated according to manufacturer's instructions. RNA
extracts were quantiﬁed spectrophotometrically, pre-treated with
RNase-free DNase I (Thermo Fisher Scientiﬁc Inc., Waltham, MA, USA)
according to manufacturer's instructions, to remove residual genomic
DNA, then reverse transcribed using High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems), also according to manufac-
turer's instructions. Quantitative PCR of cDNA used StepOne Plus PCR
instrument (Applied Biosystems), with initial denaturation for 20 s at
95 °C, 40 cycles of 3 s at 95 °C, 30 s at 60 °C, and a ﬁnal melt-curve step
of 15 s at 95 °C, 60 s at 62 °C, and 15 s at 95 °C. Reactions using custo-
mized gene-speciﬁc primers (Supplementary Table S1) were run in
duplicate, with 3.125–50 ng cDNA (depending on the target gene),
0.5 μM of each primer, and Fast SYBR Green Master Mix (Applied
Biosystems). To minimize technical bias, samples from all treatments
for a given gene and tissue were analyzed on the same plate, where
possible. Measurements that exhibited divergent melting temperatures
or ampliﬁcation curves were excluded and analyses repeated.
Quantiﬁcation cycles (Cq) and ampliﬁcation eﬃciencies (E) were cal-
culated using the online tool Real-time PCR Miner and Cq values were
corrected for among-plate bias and standardized against the mean of
two reference genes, β-actin and RPL5.
2.3. Drosophila strains and culture
Drosophila strains used in the study were 7 transgenic lines for C.
intestinalis AOX constructed in-house and described previously: UAS-
AOXF6, inserted on chromosome 2 [34], UAS-AOXF24, inserted on
chromosome 3 [34] and UAS-AOX8.1, inserted by ΦC31 recombination
at a lower-expression site on chromosome 2 [38], each containing the
AOX coding sequence placed under the control of the exogenously
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supplied GAL4 transcription factor; tubAOX35, tubAOX112 and tubAOX7,
containing insertions on chromosomes X, 2 and 3, respectively, of the
AOX coding sequence under the control of the α-tubulin promoter; and
UAS-mutAOX2nd, bearing a mutated, catalytically inactive AOX variant
also under GAL4 control, on chromosome 2. We also generated lines
2xtubAOX, homozygous for both the tubAOX112 and tubAOX7 insertions,
and 3xtubAOX, homozygous additionally for tubAOX35. Recipient line
w1118 was used as a control for all transgenic lines except those created
by ΦC31 recombination, for which a line with the UAS-containing
vector inserted at the same site as UAS-AOX8.1 and UAS-mutAOX2nd,
UAS-empty, was used. An additional control, UAS-GFP (Stinger), ex-
pressing nuclear-localized GFP under GAL4 control, was used in some
experiments. Flies were maintained and cultured on standard high-
sugar medium [34] at 18 or 25 °C, with 12 h cycles of light and dark-
ness, except where indicated in speciﬁc experiments.
2.4. Developmental assays
To test eﬀects of temperature, developmental assays were con-
ducted at 12, 15, 18, 25, and 29 °C, as follows. 20 pre-mated females, in
the presence of 10 males of the same line, were allowed to lay eggs for
≤24 h at 25 °C in a total of four vials per experiment. The eggs were
counted, transferred to the indicated temperatures, and the vials
monitored daily for the appearance of pupae and adults. Egg-to-pupa
viability was calculated for each vial as the ratio between the total
number of pupae and the total number of eggs laid. Egg-to-pupa and
egg-to-adult developmental time was determined by recording the
number of pupae or adults per vial on successive days relative to the
day of egg laying. Experiments were performed in duplicate at 12 and
15 °C, and in triplicate at other temperatures. To test eﬀects of the
composition of the culture medium, ﬂies of a given genotype or crosses
as indicated in ﬁgure legends were grown on standard high-sugar
medium or on a low-nutrient medium comprising, except where stated,
3.5% yeast and 5% glucose in standard agar with antimicrobials (nia-
pigin and propionic acid). Pupae per vial and the number of eclosed
adults were recorded.
2.5. Light microscopy of pupae
Uneclosed pupae, dissected from the pupal case if suﬃciently ad-
vanced developmentally, were visualized using a Nikon SMZ 745T
zoom stereomicroscope.
2.6. Protein extraction and analysis
Batches of 10 larvae or ﬂies were snap frozen at−80 °C and crushed
in an Eppendorf tube in 100 μl of lysis buﬀer, comprising 0.3% SDS in
PBS plus protease inhibitor cocktail (Roche). Following incubation for
15min at room temperature and centrifugation for 10min at
15,000gmax at room temperature, supernatants were decanted and
protein concentrations measured by NanoDrop spectrophotometry
(ThermoFisher Scientiﬁc). After dilution with water and 5× SDS-PAGE
sample buﬀer, 63 μg protein aliquots in 20 μl were resolved on 12%
polyacrylamide gels, wet-blotted to nitrocellulose membrane, washed
in PBS-Tween, blocked for 3 h with 5% nonfat milk in PBS-Tween at
room temperature, and reacted with custom-made rabbit anti-AOX
antibody [34], 1:10,000 overnight at 4 °C. After 5×5min washes in
PBS-Tween, the membrane was reacted with secondary antibody (goat
anti-rabbit, Vector Laboratories, 1:10,000) for 1 h at room temperature,
re-washed, processed for imaging using Luminata™ Crescendo (Milli-
pore) for 5min, then imaged for chemiluminescence using BioRad
ChemiDoc MP. Equal loading was conﬁrmed by staining the membrane
with Ponceau S for 5min, washing with water and plain imaging.
Images were optimized for brightness and contrast and cropped, rotated
and masked for clarity, but not manipulated in any other way.
Fig. 1. AOX and NDX induction by environmental stressors in Ciona intestinalis.
Reverse transcription quantitative real-time PCR (RT-qPCR) analysis of the levels of AOX and NDX transcripts in RNA extracted from the indicated tissues of C.
intestinalis adults, treated as indicated (see Materials and Methods): (A) for 6 h at oxygen levels of 1.62 (hypoxia), 7.92 (normoxia) or 15.94 (hyperoxia) mg/l or for
8 h in 0 (control), 100 or 300 μM sulﬁde, n=6 for each group, in 2 aquaria; (B) for 6 h with an oxygen level of 1.96mg/l (hypoxia), or 100 μM sulﬁde or the
combination of both (1.91mg/l O2, 100 μM sulﬁde), n= 12 for each group, in 4 aquaria. The corrected Cq statistic, representing relative transcript levels normalized
against two reference genes, was calculated as described in Materials and Methods, with data plotted as marginal model means ± 95% CI, showing data points for
individual animals in grey. Panel (A) is a subset of the data shown in Fig. S1A and S1B, omitting NDX and indicator genes. For statistical analyses, see Supplementary
Tables S2 and S3, relating to the data shown in panels (A) and (B), respectively. Note that the animals used in the experiment of panel (B) were a mixture of C.
intestinalis types A and B, currently proposed as distinct species [77]. The primers used recognize RNA from both C. intestinalis types, and the data shown in the ﬁgure
are normalized to type B (see Supplementary Table S3) for comparability with other experiments, where only type B was used.
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3. Results & discussion
3.1. AOX and NDX are induced in Ciona by hypoxia and sulﬁde
To address the question of the functional roles of NDX and AOX in
animals, we focused on C. intestinalis, the organism that has been used
as the source for the aRC transgenes that we have expressed in ﬂies,
mice and human cells. We subjected Ciona adults to a set of stressors
experienced in the natural environment, then analyzed NDX and AOX
induction at the RNA level in diﬀerent tissues (Figs. 1, S1). Both AOX
and NDX were induced by hypoxia (Figs. 1A, S1A) or exposure to sul-
ﬁde (Figs. 1A, S1B) in heart, neural complex and, to a lesser extent, in
stomach. Physiologically stressful temperature or heavy-metal exposure
did not induce the expression of aRC mRNAs (Fig. S1C, S1D), whilst the
eﬀects of hypoxia and sulﬁde were additive, at least for AOX in the
tissues showing the greatest induction (Fig. 1B). These responses
therefore result from independent sensing and signal transduction
processes. Sulﬁde is a naturally occurring inhibitor of cytochrome
oxidase, against which Ciona AOX is able to protect mammalian cells
(Fig. S1E), providing a rationale for its induction in sulﬁde-containing
seawater. AOX induction by hypoxia is more unexpected, since the
enzyme requires oxygen as a substrate just as does cytochrome oxidase.
However, AOX maintenance does not require the elaborate biogenetic
program of the cytochrome-containing complexes cIII and cIV. In par-
ticular, the pathway for haem biosynthesis in all higher eukaryotes
involves two oxygen-dependent steps: coproporphyrinogen oxidase
consumes two molecules of oxygen, releasing two each of water and
CO2 [46], whilst oxygen is used as the terminal electron acceptor for the
next step in the pathway, catalyzed by protoporphyrinogen oxidase
[47]. AOX catalysis depends on a diiron centre rather than a haem
cofactor. Therefore, AOX biosynthesis should not be aﬀected by dis-
turbed haem biosynthesis during prolonged hypoxia. Another possible
rationale for AOX expression being responsive to hypoxia is to minimize
ischemia/reperfusion injury by ROS, when the system becomes reox-
ygenated, but whilst the RC carriers are still in the reduced state. In a
parallel study in molluscs, AOX was recently shown to be induced under
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Fig. 2. AOX expression in Drosophila accelerates development at low temperatures.
(A) Egg-to-pupa development time of ﬂies of the indicated genotypes and culture temperatures (means ± SD for ≥100 ﬂies in each case, cultured in 8–12 vials in
2–4 biological replicates). For tabulated data and statistical analysis see Supplementary Table S4. (B) Egg-to-adult development time of ﬂies of the indicated
genotypes and culture temperatures (means ± SD for a total of 8–16 vials in each case, from 2 to 4 biological replicate experiments). For clarity, only the eﬀects of 2
and 3 copies of the tubAOX transgene versus the w1118 background strain are shown in the ﬁgure. Complete tabulated data and statistical analysis are presented in
Supplementary Table S5. (C) Egg-to-pupa viability of ﬂies of the indicated genotypes, cultured at diﬀerent temperatures, as shown: means ± SD for 8–12 vials from
2 to 4 biological replicates in each case. For complete tabulated data and statistical analysis see Supplementary Table S6. Note that, for clarity, data for the 29 °C
stress condition is omitted from the ﬁgure. Although AOX was also beneﬁcial at this temperature, the relationship with gene dosage was less clear than at low
temperatures, compared with standard growth conditions of 18–25 °C where AOX was neutral.
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hypoxia in a freshwater bivalve [48].
Possible medical implications: What are the potential implications for
this ﬁnding for the use of AOX in therapy? Toxic levels of sulﬁde as well
as oxygen-deprivation are conditions experienced by animals in the
natural environment but are also found in humans in cases of disease.
Although low levels of hydrogen sulﬁde act in endocrine signaling and
vasorelaxation [49–52], natural over-production or lack of detoxiﬁca-
tion of H2S can also become pathological, with cIV as a major target. A
frequent cause of disturbed H2S metabolism is the alteration of the gut
microbiota by antibiotic use, which has been implicated in ulcerative
colitis and other intestinal diseases [51]. Sulﬁde can also accumulate in
the body as a secondary eﬀect of inherited disorders, notably ethyl-
malonyl encephalopathy, now recognized as a mitochondrial disease
[53]. The ability of AOX to protect against sulﬁde toxicity thus has the
same double-edged aspect as H2S itself. Where sulﬁde is present at
pathological levels, causing impaired mitochondrial respiration, AOX
can potentially overcome the problem, if applied therapeutically.
Conversely, if cytochrome oxidase inhibition is directly operating as a
physiological sensor for H2S, for example in vasorelaxation [52], AOX
could disturb homeostatic responses. In regard to hypoxia, previous
data showed comparable eﬀects of low oxygen on the activities of AOX
and cytochrome oxidase [54]. However, because the subunit-isoform
composition of cIV varies between tissues [55], with some combina-
tions exhibiting altered kinetic properties in regard to oxygen, it cannot
be concluded that AOX will perform comparably to cIV in all tissues and
conditions. Since solid tumours represent a pathologically important
low-oxygen environment, the expression of AOX to manage other dis-
eases may favour (or disfavour) the growth of speciﬁc tumour types,
leading to unintended consequences.
3.2. AOX expression promotes temperature-dependent growth acceleration
Previous studies of Drosophila transgenic for Ciona AOX showed that
ubiquitous AOX expression resulted in a slight but statistically sig-
niﬁcant developmental delay (egg-to-adult timing), and exaggerated
weight loss as young adults [34]. Both of these observations are con-
sistent with the idea that AOX might become at least partially active
during development, resulting is less eﬃcient use of stored nutritional
resources. In such a case, by catalyzing the same redox chemistry as the
mitochondrial cytochrome chain, but without energy conservation via
proton-pumping, AOX should simply convert a greater proportion of
released free energy to heat, as already demonstrated in vitro [56]. One
corollary of this is that activation of AOX could potentially be beneﬁcial
at low temperatures that are otherwise sub-optimal for the completion
of development, via a thermogenic eﬀect.
To test this we made use of a set of transgenic ﬂy lines expressing
AOX under the control of the α-tubulin promoter in one, two or three
diploid copies. These were cultured under diﬀerent temperatures. The
period of larval development, characterized by biomass accumulation,
was essentially unaﬀected by AOX expression at the standard growth
temperature of 25 °C, or at the elevated temperature of 29 °C (Fig. 2A).
However, at low temperature, when the growth period was greatly
extended, AOX expression resulted in a markedly increased rate of
development, which was most pronounced in ﬂies bearing three copies
of the transgene, and at the lowest temperature tested, 12 °C (Fig. 2A).
Pupal development was less aﬀected by AOX (Fig. 2B): instead, the
2–3 d acceleration produced during larval development was simply
maintained during metamorphosis (Fig. 2B). At low temperature we
also observed a signiﬁcantly higher proportion of eggs able to reach the
pupal stage, also correlating with increased AOX gene dosage (Fig. 2C).
As in other contexts where rapid growth prevails (cancer cells, yeast
in exponential growth phase in glucose-rich medium) ATP production
in Drosophila larvae depends largely on glycolysis, considered as the
main high-capacity pathway for generating both energy and organic
intermediates for biosynthesis. Under such conditions, mitochondrial
respiration nevertheless remains indispensable, since the processing of
carbon skeletons for biosynthesis depends on the TCA cycle which, in
turn, requires the eﬃcient reoxidation of primary electron carriers via
the respiratory chain, a condition recognized by Warburg as ‘aerobic
glycolysis’ [57]. The capacity of the system to fulﬁl this role does not
appear to be limiting in larvae grown under standard conditions, since
AOX expression has no eﬀect on larval growth rate at 25 °C (Fig. 2A). If
the TCA cycle were being restrained by the coupling of the RC to ATP
production, enzymatically active AOX should accelerate the cycle, since
it produces less ATP per molecule of ubiquinol oxidized. However, at
low temperature, where all chemical reactions are slowed, growth
proceeds much more slowly, e.g. larvae cultured at 12 °C grow
at< 20% of the rate exhibited by those grown at 25 or 29 °C (Fig. 2A).
The clear growth acceleration provided by AOX expression under these
conditions can thus be attributed either to its ability to alleviate lim-
itations on electron ﬂow, which might constrain the TCA cycle at low
temperature, or else to a direct thermogenic eﬀect raising the tem-
perature of the mitochondria [58] and of the whole organism. In whole
or permeabilized mammalian cells grown at 37 °C [78], or in mi-
tochondrial homogenates from ﬂies grown and assayed at diﬀerent
temperatures between 18 and 29 °C [34], AOX expression did not
support 100% of the respiratory capacity of cIII under uninhibited
conditions. Thus, we strongly favour the second mechanistic hypoth-
esis, whereby a direct thermogenic eﬀect actually warms larvae suﬃ-
ciently to accelerate developmental processes which are sub-optimal at
low temperature. Testing this will not be straightforward, however,
since Drosophila larvae are opaque to the dyes and reporters thus far
developed as intracellular temperature reporters.
Possible medical implications: based on these ﬁndings, the use of AOX
to compensate RC defects potentially carries the unexpected risk that it
could create metabolic conditions that promote the growth of some
tumours. The role of metabolism in cancer has recently attracted a lot of
interest, although it is misleading to assert that this role is always in the
same direction. Rather, the relative dependence on glycolysis versus
OXPHOS varies greatly between tumour types, or even between a single
cancer at diﬀerent stages of the disease [59]. However, rapid growth is
generally associated with the high-throughput glycolytic pathway as
the major source of ATP, but accompanied by a repurposing of the TCA
cycle (and OXPHOS) for anabolism [59], which applies both to devel-
oping Drosophila larvae and to most tumour cells. Although the growth
acceleration conferred upon ﬂy larvae by AOX was seen only at low
temperature, the mechanism could potentially operate under other
stress conditions in cancer cells, where the processing of carbon ske-
letons for biosynthesis could potentially be limited by insuﬃciency of
the RC. An obvious cause of such insuﬃciency would be the clonal
ampliﬁcation of mtDNA mutations during the establishment of the tu-
mour, which could then limit its growth in later stages of the disease.
Many tumours are indeed found to harbour deleterious mtDNA muta-
tions. In such cases, AOX could alleviate growth constraints arising
from mutations in genes for subunits of cIII or cIV or from mutations in
the mitochondrial protein synthetic apparatus where cIII or cIV were
the most aﬀected products, such as the A8344 MERRF mutation [60].
Note, however, that it is also possible to construe an opposite argument,
in cases where a cIII defect promotes tumour growth or metastasis
through increased ROS production [61]. In such cases, AOX may relieve
this eﬀect and restrict cancer progression. The inferred thermogenic
eﬀect of AOX raises additional potential issues, as discussed further in
the following section.
3.3. AOX-expressing ﬂies show temperature dependent lethality on nutrient-
poor media
The earlier observations of a slight developmental delay and mild
weight loss in adult ﬂies expressing AOX suggest that AOX-expressing
ﬂies use nutritional resources less eﬃciently than their wild-type
counterparts. To investigate this issue further, we cultured ﬂies ubi-
quitously expressing AOX, as well as a wide panel of controls, on
S. Saari et al. BBA - Molecular Basis of Disease 1865 (2019) 854–866
859
nutrient-poor media. On standard high-sugar medium [62], AOX-ex-
pressing ﬂies eclosed at the same frequency as controls (Fig. 3A),
whereas on low-nutrient medium, containing only 3.5% yeast and 5%
glucose plus agar and antimicrobials, most (~80%) AOX-expressing
ﬂies died as pupae (Fig. 3A). Controls, including AOX transgenic but
non-expressing ﬂies, as well as ﬂies expressing GFP, eclosed almost
normally on this medium (Fig. 3A). A second AOX transgenic line be-
haved similarly (Fig. 3B), whereas a third, in which AOX expression is
much lower [38], as well as a transgenic line expressing a catalytically
inactive variant of AOX [38] did not (Fig. 3C). AOX-expressing pupae
cultured on low-nutrient medium died at various diﬀerent stages of
metamorphosis (Fig. 3D), suggesting that they had exhausted a general
component required for the completion of development, rather than
becoming blocked in a stage-speciﬁc process. When the ﬂies were cul-
tured in tightly temperature-controlled incubators, the phenotype was
found to be extremely temperature sensitive (Fig. 4A). Speciﬁcally, at
22 °C AOX-expressing ﬂies eclosed at a near-normal frequency on low-
nutrient medium, whereas at 25 °C, and more acutely at 26 °C, they
mostly died as pupae, whilst at 27 °C, hardly any AOX-expressing ﬂies
eclosed even when cultured on standard medium. At 29 °C control ﬂies
also showed a decreased eclosion frequency, especially on the low-nu-
trient medium. The phenotype, including its modulation by tempera-
ture, was maintained even when the glucose level was raised to 10%
(Fig. 4A). Although this temperature-dependence may partly be ex-
plained by the increased expression of the transgene at high tempera-
ture, under the inﬂuence of the daGAL4 driver (Fig. 4B), the similarities
with the behaviour of control ﬂies at high temperature suggests a
contribution also from the thermogenic eﬀect of the enzyme. Increasing
the yeast concentration in the low-nutrient medium to 10% also failed
to reverse the developmental phenotype, whilst decreasing it to 1% led
to developmental arrest for a majority of wild-type pupae as well
(Fig. 4C). Even when cultured on medium containing only yeast and
agar, control ﬂies eclosed normally, whilst> 90% of AOX-expressing
ﬂies died as pupae.
These ﬁndings imply that components of our standard high-sugar
medium must be crucial in enabling AOX-expressing ﬂies to complete
development. The standard medium is a complex mixture containing
several highly heterogeneous components (including yeast, as well as
treacle, soya ﬂour and maize ﬂour). Further analysis will be needed to
establish which speciﬁc nutrient(s) are essential for AOX ﬂies.
As already indicated, Drosophila development involves distinct
phases. During metamorphosis, the pupa does not feed, instead relying
upon biomass accumulated during larval development. Metamorphosis
involves drastic tissue reorganization, fuelled largely by stored trigly-
cerides [63]. If AOX were to become activated under such conditions,
ATP generation could be severely curtailed, since the pathways of tri-
glyceride breakdown (via glycerol‑3‑phosphate dehydrogenase and
fatty-acid β-oxidation) give rise to reducing equivalents that mostly
enter the respiratory chain via ubiquinol at cIII. This may account for
developmental failure, if insuﬃcient such resources had been accu-
mulated prior to metamorphosis. Alternatively, if AOX were activated
in larvae under low nutrient conditions, impairing the eﬃciency of
biosynthesis, this may account for insuﬃcient amounts of stored tri-
glycerides being laid down, and leading to developmental failure at a
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later stage.
Possible medical implications: our ﬁndings can be considered as a
further example of the increasingly documented link between nutrition,
mitochondrial function, and the accumulation and use of fat reserves.
Dysregulation of the relevant processes is increasingly considered to
underlie obesity and other metabolic disorders [56,64,65]. Here we
have shown that altering the balance between mitochondrial substrate
utilization and energy production can have profound implications for
biological processes, leading to developmental arrest. Trying to draw
exact parallels between insect and mammalian physiology may be
misleading, especially given that mammals show precise thermo-
regulation and possess a tissue dedicated to this role, brown fat, al-
though its importance declines with age [66]. If AOX expression leads
more globally to increased fat burning, or decreased fat accumulation,
its use in pathologies with a metabolic dimension may have important,
and in some cases undesired consequences. An analogy may be drawn
with human CPT2 deﬁciency, where the inability to use long-chain fatty
acids as a metabolic fuel leads either to early lethality or to sensitivity
to starvation, depending on the severity of the mutation [67–69]. A
similar phenotype is produced in ﬂies homozygous for a null mutation
in Drosophila CPT2. Once more, there is also a potential relevance in
cancer, where metabolic inﬂexibility, i.e. loss of the ability to survive
on diﬀerent substrates, is a common observation [70]. Conversely, AOX
may be of potential use to correct metabolic imbalances, or at least to
investigate the role of mitochondrial energetics in pathology. Similar
ideas have been proposed elsewhere for treatments that induce ther-
mogenic or energetically ‘futile’ pathways [71]. Indeed, thermogenesis
is clearly a feature of the immune response, and AOX may oﬀer one
route to intensify it and target it more eﬀectively.
3.4. AOX accelerates recovery from cold-induced paralysis in Drosophila
adults
The above ﬁndings suggest that AOX may be functionally thermo-
genic under speciﬁc physiological conditions. Even though the tran-
scription of the gene was not induced in Ciona by cold temperature (Fig.
S1), activation in the cold may be an inherent property of the enzyme.
We therefore tested its eﬀects on cold-exposed ﬂies. In trials, 12 days at
4 °C was suﬃcient to kill 80–90% of control ﬂies, whereas ﬂies homo-
zygous for 3 copies of the tubAOX transgene in the same genetic
background all survived this treatment. A shorter period of cold ex-
posure (15 h at 4 °C in food-containing vials) was non-lethal to all ﬂies,
but induced paralysis. When vials were transferred to 24.5 °C, the AOX-
expressing ﬂies started to become mobile after 25min, whereas control
ﬂies only began to emerge from paralysis after 45min (Fig. 5).
Possible medical implications: the simplest interpretation of these
results is that AOX becomes at least partially active at low temperature,
physically warming the organism to mitigate lethality at low
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temperature and accelerating recovery from cold-induced paralysis.
Since a thermogenic eﬀect of AOX in plants is well documented
[17,18], our ﬁndings that it may act similarly in some animals is not
implausible. However, if AOX were deployed therapeutically in
homeotherms such as humans, excess heat production should activate
thermoregulatory mechanisms and, in an extreme situation, might
overwhelm them. Moreover, if the excess heat is not eﬃciently con-
ducted away from the mitochondria, as suggested by recent studies
[58], it may lead to unpredictable changes in enzyme activities and
disturb, rather than restore, metabolic homeostasis. On the other hand,
if properly regulated, AOX may provide a possible treatment for some
forms of obesity, by increasing the amount of fat or carbohydrate that
must be burned to generate a given amount of ATP, but without the
potentially harmful eﬀects arising from loss of mitochondrial mem-
brane potential produced by chemical uncouplers or uncoupling pro-
teins such as UCP1.
3.5. AOX has other unexpected eﬀects on development and physiology
When undertaking the expression of Ciona AOX in metazoan models
such as Drosophila or the mouse, we initially considered the possibility
that widespread expression of the enzyme would be lethal, due to its
ability to short-circuit mitochondrial ATP production when functionally
active. We initially made the surprising observation that ubiquitous
AOX expression was fully compatible with development and an osten-
sibly normal physiology in both ﬂies and mice [34,72]. This, plus the
known properties of the plant and algal enzyme, which is activated only
under conditions of over-reduction of the quinone pool [3,4], then led
us in the opposite direction. If AOX is only active under conditions of
metabolic imbalance and oxidative stress, it can be proposed as a po-
tential wide-spectrum therapeutic tool that is benign in the unstressed
organism. The ﬁndings presented above now argue for an intermediate
conclusion, namely that AOX, whilst displaying clear beneﬁcial eﬀects,
does impact physiological processes in ways that were not expected,
even if they can be rationalized from the known properties of mi-
tochondria and cells. Activation of AOX by speciﬁc metabolites or en-
ergetic states can potentially interfere with speciﬁc developmental
processes. The causes and consequences are not easy to predict me-
chanistically, since we do not have a full description of the metabolic
changes that occur in animal development, nor do we yet have a clear
idea of how the activity of AOX from Ciona is regulated. Some other
examples from our recent work illustrate these points.
AOX-expressing ﬂies of both sexes are fertile and produce normal
numbers of oﬀspring [34]. However, when tested in a direct competi-
tion assay, as illustrated in Fig. 6, AOX-expressing males were system-
atically out-competed by control males [73]. We traced the reason for
this abnormality to a relative lack of sperm production by AOX-ex-
pressing males [73]. Surprisingly, this did not appear to be due to AOX
expression in the germline, which was seen only at low levels com-
parable with the detection limit, but to its expression in the pigment
cells of the testis sheath. Moreover, it was associated not with a block
on diﬀerentiation as such, but with its spatial disorganization and
consequent failure to accumulate mature sperm into the seminal ve-
sicle. The precise mechanistic basis of the phenotype remains to be
elucidated, although it logically involves deranged signaling from the
mitochondria-rich pigment cells to the underlying smooth muscle, im-
peding the peristaltic movement of maturing sperm cysts. Why AOX
would be activated in those cells, and whether the eﬀect is attributable
to decreased ATP production, impaired ROS signaling, increased tem-
perature or some other process, remain open questions.
It is to be expected that metabolic stress can also lead to transient
activation of AOX, blunting the signals that enable organisms to re-
spond to and negate such stresses. Thus, there may be instances where
AOX impairs regenerative responses and exacerbates stress-induced
damage. Conversely, we have identiﬁed several contexts where AOX
expression appears able to potentiate normal signaling or to quench
abnormal signaling, in either case preventing a pathological outcome.
Perhaps the most remarkable example is the ability of AOX to prevent a
range of developmental dysmorphologies induced by abnormal nuclear
receptor activity. These are provoked by the combined action of a
modiﬁed GAL4 driver (‘GeneSwitch’), which includes the ligand-
binding domain of the progesterone receptor, plus an excess of the ar-
tiﬁcial steroid that induces it, but is brought about in the absence of any
transgene. Expression of AOX, even from a GAL4-independent pro-
moter, was able to largely prevent the appearance of these dysmor-
phological phenotypes, including cleft thorax or abdomen, apoptotic
wing segments, malformed legs or sensory bristles [74]. AOX expres-
sion was also able to correct the most frequently observed of these
abnormalities, cleft thorax, when induced by a completely separate
manipulation, through the impairment of Jun N-terminal kinase (JNK)
signaling in the dorsal thoracic midline during metamorphosis [75].
AOX was also found to promote cell migration in immortalized mouse
embryonic ﬁbroblasts, and to counteract the negative eﬀects on this
process of at least one protein kinase inhibitor [75].
Our studies of the properties of mouse models is much less advanced
at this point, but one intriguing observation is the fact that AOX is able
to block the lethal eﬀects of lipopolysaccharide (LPS), in a mouse model
of sepsis [76]. This ﬁnding was part of a wider study to understand the
role of mitochondria in cytokine release by activated macrophages. If
not properly controlled, this is believed to lead to septic shock and
organ failure. AOX was inferred to provide a shunt for blocked elec-
trons, normalizing mitochondrial metabolism in macrophages and
preventing excess ROS production arising from reverse electron ﬂow
through cI. This study provides an important benchmark for how AOX
can be used to probe the mitochondrial role in diverse pathologies,
physiological and developmental processes. The lesson from studies in
Drosophila is that a mitochondrial role should always be considered in
any complex or unexplained pathological phenotype, and the avail-
ability of transgenic lines for AOX and NDX provides a way of testing
this whenever a credible animal or cell-culture model exists.
Possible medical implications: it is arguably fanciful to translate
knowledge directly from Drosophila or even the mouse to human dis-
ease, without exhaustive validation studies. Therefore, the fact that
AOX impairs male reproductive competitiveness or corrects cleft thorax
in ﬂies does not mean that male infertility must automatically be con-
sidered a mitochondrial disease or that AOX could somehow be de-
ployed to treat midline closure defects in human development, such as
spina biﬁda or cleft palate. Nevertheless, the use of AOX and NDX to
probe mitochondrial involvement in disease-related processes should
provide powerful clues that could have unforeseen applications in
medicine.
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4. Conclusions and perspectives
Our global understanding of metabolism and how it impacts cell
signaling remains limited. Thus, to predict the eﬀects of introducing a
major metabolic modiﬁcation, such as the introduction of AOX (or
NDX) into organisms that lack the aRC, is fraught with diﬃculties, and
we should expect surprises. As summarized in Fig. 7, metazoan AOX,
when activated by the accumulation of reduced quinol, plus other, as
yet unidentiﬁed metabolic trigger(s), accelerates mitochondrial meta-
bolism compared with an inhibited condition that it alleviates. How-
ever, it generally decelerates metabolism compared with the fully un-
inhibited condition, when electrons are able to pass freely to complex
III, as inferred from the measured oxygen consumption of cultured cells
[78]. Mitochondrial NADH oxidation and ATP production should follow
similar trends, although neither has yet been speciﬁcally measured.
ATP production should be the more severely aﬀected, given that a much
greater proportion of the energy released by AOX-supported respiration
is converted to heat rather than being used for ATP synthesis. However,
because the net eﬀects on metabolism may be diverse and complex,
total cell NAD+ and ATP levels might remain stable or even rise. Si-
milar but opposite considerations apply to ROS. Mitochondrial super-
oxide production is decreased by AOX in cells where OXPHOS is in-
hibited, but increased compared with fully uninhibited conditions [78].
How this aﬀects ROS in the rest of the cell is again not clear. Much
remains to be documented and tested. Because the metabolic eﬀects of
AOX expression are not fully predictable, the many cellular regulatory
pathways that respond to ROS, ATP, NAD, TCA cycle intermediates and
other metabolites, as well as mitochondrial heat production, are likely
to be aﬀected in complex ways, leading to the readouts observed in our
studies and elsewhere. These, in turn, are very likely to aﬀect the me-
tabolic triggers that govern AOX activation.
About NDX we know even less at this time. For example, when
expressed in mammalian cells, AOX does not interact with any of the
mitochondrial OXPHOS complexes [54,72], but this has not yet been
tested for NDX. A further intriguing question arises as to the functional
interactions of AOX and NDX. In principle, if simultaneously active,
they would catalyze a completely non proton-motive respiratory chain,
although it is not known if this ever happens in a physiological situa-
tion, or whether the two enzymes are able to interact physically. An
important question is how far they inﬂuence each other's activity, and
which of them represents the eﬀective control point for the aRC. In
Drosophila, they can at least synergize functionally, e.g. in the tko25t
mutant [41], as already mentioned. Thus, their combined eﬀects on
metabolism may diﬀer from that of either alone. If the aRC enzymes are
to be used in clinical applications, we will need a much better under-
standing of all these eﬀects, including how both enzymes are naturally
regulated, how they interact, how they access and modify the quinone
pool(s), what broader impact they have on metabolism, and the precise
mechanisms by which they inﬂuence cell signaling.
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The principle of the sperm competition assay is that Drosophila females, when mated, naturally store the sperm of the male partner, which is used to fertilize oocytes
over several days, as they mature. However, females are still receptive to mating with a second male, whose sperm can then compete with that from the original male.
In the scheme shown, (A) a white-eyed female is ﬁrst mated to a white-eyed male, producing white-eyed progeny. In a second mating (B), the same female is re-mated
with a red-eyed male. The standard outcome of such an experiment, illustrated in (C), is that the sperm from the second male displaces or out-competes that from the
ﬁrst. Since the red-eye allele is dominant, most of the progeny after the second mating will have red eyes. If, however, the sperm from the second male competes
poorly, as illustrated in (D), most of the progeny will arise from oocytes fertilized by sperm from the original male, and will this have white eyes. As an internal
control, the assay is usually done both ways around, i.e. with a second full experiment in which the ﬁrst mating is performed with red-eyed males. These reciprocal
setups are often described as the ‘oﬀensive’ and ‘defensive’ paradigms. In the experiments that were conducted, the sperm of AOX-expressing males was found to
compete poorly compared with controls (see [73] for details).
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